Burcu Arpinar Yigitbas

Burcu Arpinar Yigitbas

Auto-generated profile, based on publicly available information

Burcu Arpinar Yigitbas

Istanbul Medeniyet University Faculty of Medicine, Goztepe Prof. Dr. Suleyman Yalcın City Hospital, Department of Pulmonology, Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2020 in Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
AGAskin Gülsen
Askin Gülsen
BYBurcu Arpinar Yigitbas
Burcu Arpinar Yigitbas
BUBerat Uslu
Berat Uslu
DDDaniel Drömann
Daniel Drömann
OKOguz Kilinc
Oguz Kilinc
Background. Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SAR2-COV-2) and was first identified in Wuhan, China, in December of 2019, but quickly spread to the rest of the world, causing a pandemic. While some studies have found no link between smoking status and severe COVID-19, others demonstrated a significant one. The present study aimed to determine the relationship between smoking and clinical COVID-19 severity via a systematic meta-analysis approach. Methods. We searched the Google Scholar, PubMed, Scopus, Web of Science, and Embase databases to identify clinical studies suitable for inclusion in this meta-analysis. Studies reporting smoking status and comparing nonsevere and severe patients were included. Nonsevere cases were described as mild, common type, nonintensive care unit (ICU) treatment, survivors, and severe cases as critical, need for ICU, refractory, and nonsurvivors. Results. A total of 16 articles detailing 11322 COVID-19 patients were included. Our meta-analysis revealed a relationship between a history of smoking and severe COVID-19 cases (OR=2.17; 95% CI: 1.37–3.46; P<.001). Additionally, we found an association between the current smoking status and severe COVID-19 (OR=1.51; 95% CI: 1.12–2.05; P<.008). In 10.7% (978/9067) of nonsmokers, COVID-19 was severe, while in active smokers, severe COVID-19 occurred in 21.2% (65/305) of cases. Conclusion. Active smoking and a history of smoking are clearly associated with severe COVID-19. The SARS-COV-2 epidemic should serve as an impetus for patients and those at risk to maintain good health practices and discontinue smoking. The trial is registered with the International Prospective Register of Systematic Reviews (PROSPERO) CRD42020180173.

23 June 2022 in Medeniyet Medical Journal
Verified
Journal Article
Open access
EYEsra Ertan Yazar
Esra Ertan Yazar
ENElif Yelda Niksarlioglu
Elif Yelda Niksarlioglu
BYBurcu Yigitbas
Burcu Yigitbas
MBMesut Bayraktaroglu
Mesut Bayraktaroglu
In this study, we aimed to investigate the compatibility of modified Medical Research Council (mMRC) and COPD assessment test (CAT) scores of chronic obstructive pulmonary disease (COPD) patients in terms of evaluation of their symptom status. The study was planned as a single-center, cross-sectional study. Statistically four separate receiver operating characteristic (ROC) curves of CAT scoring were generated for mMRC scores of 1 to 4. Two hundred twenty eight patients with stable COPD, mean age 64.2±8.2 and 88.6% male were included. A strong positive correlation was detected between CAT and mMRC (r=0.60, p<0.001). However, it was observed that 32 patients had mMRC<2 but CAT≥10, while 21 patients had CAT<10 but mMRC≥2. Thus, in 53 patients CAT and mMRC scores were not identical in terms of assessed symptom status. According to the ROC analysis, the mMRC scores of 1 to 4 were most compatible with the CAT scores of 10, 10, 15, and 20, respectively. Expanding current data represents that CAT score of 10 could be more compatible with mMRC score of 1. Moreover we think although a high mMRC or CAT score may be sufficient to assign patients to high symptom groups, it is needed to evaluate mMRC and CAT together to assign a patient to a low symptom group. In this way misclassification of the patients with high symptoms due to insufficient symptom evaluation as if they have low symptoms can be prevented.

6 March 2014 in Multidisciplinary Respiratory Medicine
Verified
Journal Article
Open access
PDF file
SYSibel Yurt
Sibel Yurt
CKCanan Kucukgergin
Canan Kucukgergin
BYBurcu Arpinar Yigitbas
Burcu Arpinar Yigitbas
ŞSŞule Seçkin
Şule Seçkin
HTHüseyin Cem Tigin
Hüseyin Cem Tigin
AKAyşe Filiz Koşar
Ayşe Filiz Koşar
To evaluate and compare the diagnostic efficiency of serum (s) and pleural (p) levels of adenosine deaminase (ADA)-1, ADA-2, total ADA, and interferon-gamma (IFN-γ) for the differential diagnosis of pleural tuberculosis (TB).

17 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
AGAskin Gülsen
Askin Gülsen
BYBurcu Arpinar Yigitbas
Burcu Arpinar Yigitbas
BUBerat Uslu
Berat Uslu
DDDaniel med. Daniel Drömann
Daniel med. Daniel Drömann
OKOguz Kilinc
Oguz Kilinc
Background: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SAR2-COV-2), and was first identified in Wuhan, China in December of 2019, but quickly spread to the rest of the world, causing a pandemic. While some studies have found no link between smoking status and severe COVID-19, others demonstrated a significant one. The present study aimed to determine the relationship between smoking and clinical COVID-19 severity via a systematic meta-analysis approach. Methods: We searched the Google Scholar, PubMed, Scopus, Web of Science, and Embase databases to identify clinical studies suitable for inclusion in this meta-analysis. Studies reporting smoking status and comparing non-severe and severe patients were included. Non-severe cases were described as mild, common type, non-intensive care unit (ICU) treatment, survivors, and severe cases as critical, need for ICU, refractory, and non-survivors. Results: A total of 16 articles detailing 11322 COVID-19 patients were included. Our meta-analysis revealed a relationship between a history of smoking and severe COVID-19 cases (OR=2.17; 95% CI: 1.37–3.46; P <.001). Additionally, we found an association between the current smoking status and severe COVID-19 (OR=1.51; 95% CI: 1.12–2.05; P <.008). In 10.7% (978/9067) of non-smokers, COVID-19 was severe, while in active smokers, severe COVID-19 occurred in 21.2% (65/305) of cases. Conclusion: Active smoking and a history of smoking are clearly associated with severe COVID-19. The SARS-COV-2 epidemic should serve as an impetus for patients and those at risk to maintain good health practices and discontinue smoking.

13 May 2021 in Expert Review of Respiratory Medicine
Verified
Journal Article
Closed access
OTOnur Turan
Onur Turan
BYBurcu Arpınar Yigitbas
Burcu Arpınar Yigitbas
PTPakize Ayşe Turan
Pakize Ayşe Turan
AMArzu Mirici
Arzu Mirici
Although COPD is not one of the most common comorbidities in COVID-19 patients, it can be more fatal in this group. This study aimed to investigate the characteristics and prognosis of COPD patient...

10 March 2023 in Tuberk Toraks
Verified
Journal Article
Open access
NANurten Aysan
Nurten Aysan
GKGizem Köybaşı
Gizem Köybaşı
CSCelal Satıcı
Celal Satıcı
MDMustafa Asım Demirkol
Mustafa Asım Demirkol
BYBurcu Arpınar Yiğitbaş
Burcu Arpınar Yiğitbaş
AKAyşe Filiz Arpaçağ Koşar
Ayşe Filiz Arpaçağ Koşar
Ocrelizumab is an anti-CD20 monoclonal antibody used in the treatment of primary progressive and relapsing multiple sclerosis (MS). Although cases of organizing pneumonia have been reported in association with other antiCD20 agents such as rituximab, there is insufficient data in the literature on Ocrelizumab-associated lung involvement. Herein, we present a case of organizing pneumonia in a 37-year-old female patient with multiple sclerosis following Ocrelizumab use.